[
    [
        {
            "time": "",
            "original_text": "药企现金流Top20！应收账款占比高，智飞生物凭“新冠疫苗”现金流暴涨1532%",
            "features": {
                "keywords": [
                    "药企",
                    "现金流",
                    "智飞生物",
                    "新冠疫苗",
                    "暴涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药企现金流Top20！应收账款占比高，智飞生物凭“新冠疫苗”现金流暴涨1532%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物(300122)2021年中报点评：业绩超预期 新冠疫苗或成新增长极",
            "features": {
                "keywords": [
                    "智飞生物",
                    "中报",
                    "业绩",
                    "新冠疫苗",
                    "新增长极"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物(300122)2021年中报点评：业绩超预期 新冠疫苗或成新增长极",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "疫苗板块2021H1总结：新冠疫苗商业化价值初现 在研管线亮点颇多",
            "features": {
                "keywords": [
                    "疫苗板块",
                    "新冠疫苗",
                    "商业化价值",
                    "在研管线"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "疫苗板块2021H1总结：新冠疫苗商业化价值初现 在研管线亮点颇多",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]